.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Covington
Boehringer Ingelheim
Teva
Queensland Health
Mallinckrodt
Harvard Business School
Chinese Patent Office
Moodys
Healthtrust
Cantor Fitzgerald

Generated: July 27, 2017

DrugPatentWatch Database Preview

SERPASIL Drug Profile

« Back to Dashboard

Which patents cover Serpasil, and when can generic versions of Serpasil launch?

Serpasil is a drug marketed by Novartis and is included in four NDAs.

The generic ingredient in SERPASIL is hydrochlorothiazide; reserpine. There are thirty-one drug master file entries for this compound. Additional details are available on the hydrochlorothiazide; reserpine profile page.

Summary for Tradename: SERPASIL

Patents:0
Applicants:1
NDAs:4
Bulk Api Vendors: see list47
Patent Applications: see list6,203
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:SERPASIL at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis
SERPASIL
reserpine
ELIXIR;ORAL009115-005Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Novartis
SERPASIL-APRESOLINE
hydralazine hydrochloride; reserpine
TABLET;ORAL009296-002Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Novartis
SERPASIL
reserpine
TABLET;ORAL009115-004Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Novartis
SERPASIL-ESIDRIX #1
hydrochlorothiazide; reserpine
TABLET;ORAL011878-003Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Novartis
SERPASIL
reserpine
TABLET;ORAL009115-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Harvard Business School
QuintilesIMS
Chinese Patent Office
Chubb
Fuji
Express Scripts
Novartis
Mallinckrodt
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot